Valeant Pharmaceuticals International Inc.

Earnings Per Share Growth (%)-132.32%
Cost of Goods Sold (US$ Millions)$2,585
Current Liabilities (US$ Millions)$5,313
Total Assets (US$ Millions)$5,507
Long Term Debt$30,265
Return on Equity-5.53%
Revenue (US$ Millions)$10,447
Total Company Assets$48,965
Revenue Growth (%)27.30%
Net Income (US$ Millions)($292)
Earnings Per Share (US$)($132.32)
Total Equity (US$ Millions)$5,911
Profit Margin (%)-2.79%
Debt To Equity Ratio (%)5.12%
Inventory Turnover$1,257